UMAB contributes to antibody-driven research by supporting projects that advance scientific insight and therapeutic development.
Our research highlights illustrate the impact of UMAB-generated antibodies in academic and translational research.
A lead candidate targeting CD123 developed by Byondis was generated at the UMAB facility.
View the Byondis CD123 pipeline:
https://www.byondis.com/our-science/pipeline
New insights into Type I and Type II CD20 antibody mechanisms of action were obtained using a panel of novel CD20 antibodies generated at UMAB
(Meyer S, et al. British Journal of Haematology, May 2018).
https://researchinformation.umcutrecht.nl/en/publications/new-insights-in-type-i-and-ii-cd20-antibody-mechanisms-of-action-/
Oncode Institute – Therapeutic Antibody Research
UMAB contributes to the Oncode Therapeutic Antibody Project (UMC Utrecht) as part of the Oncode Antibody & Biologics Accelerator Platform.
https://oncodeinstitute.nl/facilities/oncode-antibody-biologics-accelerator-platform-umab-1